Literature DB >> 19218614

Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea.

Stephen B Kaye1, Timothy Neal, Steven Nicholson, Jagoda Szkurlat, Sharon Bamber, Andrew C Baddon, Sarah Anderson, Keeley Seddon, Nichola Dwyer, Andrew M Lovering, Godfrey Smith.   

Abstract

PURPOSE: To investigate the concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea.
METHODS: A biological assay was developed with corneal tissue used as a carrier for the antimicrobial. Concentration and biological activity were determined with a chemical assay and zone of inhibition (ZOI) around corneal samples with epithelial and endothelial surfaces in contact with the indicator organism. Patients undergoing penetrating keratoplasty received ciprofloxacin 0.3% or teicoplanin 1%.
RESULTS: There were good correlations between antimicrobial concentration and ZOI, when either filter paper or corneal discs were used (R(2) > 92%). Of 33 patients, the mean (median) concentration of ciprofloxacin in the cornea was 1.37 mg/L (0.46 mg/L) and 1.89 mg/L (1.44 mg/L; bioassay) in the epithelial and endothelial orientations, respectively, and 14.87 mg/L (7.41) in the cornea and 0.51 mg/L (0.42) in the aqueous (chemical assay). For teicoplanin, the mean (median) concentration in the cornea was 9.58 mg/L (0 mg/L) in the epithelial and 4.78 mg/L (0 mg/L) in the endothelial orientations (bioassay). In the chemical assay, teicoplanin could not be detected in the cornea or aqueous at the lower limit of detection of 3.6 mg/L.
CONCLUSIONS: The ZOI produced by corneal tissue provides a potential bioassay of antimicrobial activity and concentration. Although in contrast to teicoplanin ciprofloxacin shows good corneal penetration, with high endothelial-to-epithelial levels, only approximately 10% of measured levels in a chemical assay are available, according to a bioassay. Teicoplanin shows relatively poor corneal penetration through intact epithelium. These methods may be useful in evaluating the biological activity across the cornea of antimicrobials introduced into ophthalmic practice to deal with changing bacterial resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19218614     DOI: 10.1167/iovs.08-3201

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

Review 1.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

2.  Antimicrobial susceptibility and minimal inhibitory concentration of Pseudomonas aeruginosa isolated from septic ocular surface disease in different animal species.

Authors:  L Leigue; F Montiani-Ferreira; B A Moore
Journal:  Open Vet J       Date:  2016-11-15

3.  Microbial keratitis and the selection of topical antimicrobials.

Authors:  Stephen Kaye
Journal:  BMJ Open Ophthalmol       Date:  2017-05-24

4.  Ciprofloxacin self-dissolvable Soluplus based polymeric films: a novel proposal to improve the management of eye infections.

Authors:  Antonio J Guillot; Dimitris Petalas; Pari Skondra; Hortensia Rico; Teresa M Garrigues; Ana Melero
Journal:  Drug Deliv Transl Res       Date:  2021-02-02       Impact factor: 4.617

5.  Delayed-Onset Post-Keratoplasty Endophthalmitis Caused by Vancomycin-Resistant Enterococcus faecium.

Authors:  Julio C Hernandez-Camarena; Victor M Bautista-de Lucio; Alejandro Navas; Arturo Ramirez-Miranda; Enrique O Graue-Hernandez
Journal:  Case Rep Ophthalmol       Date:  2012-10-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.